New immune cell therapy aims to prevent leukemia return after transplant
NCT ID NCT06704152
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tests a new cell therapy called BSB-1001 in 38 adults with high-risk blood cancers (AML, ALL, or MDS) who are getting a stem cell transplant. BSB-1001 is made from donor immune cells that are modified to attack a specific marker on cancer cells. The goal is to see if it is safe and can prevent the cancer from coming back.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BSB-1001 (a type of immune cell therapy that targets a specific protein on cancer cells)
What this could lead to
If it works, this could help prevent blood cancers from coming back after a stem cell transplant, offering a new option for patients with hard-to-treat leukemia or MDS.
What could go wrong
This is an early-phase trial with only 38 participants, so it may not work as hoped. Risks include serious side effects like graft-versus-host disease (GVHD) or other immune reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope National Medical Center
RECRUITINGDuarte, California, 91010, United States
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
-
The Ohio State University
RECRUITINGColumbus, Ohio, 43210, United States
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
-
University of Minnesota
RECRUITINGMinneapolis, Minnesota, 55455, United States
-
Washington University at St Louis
RECRUITINGSt Louis, Missouri, 63110, United States